CDCA3在肝细胞肝癌增殖中的作用研究

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (908 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the biological behavior of cell division cycle associated protein 3 (CDCA3) in liver cancer. Methods Tissue specimens of hepatocellular carcinoma patients who underwent surgical treatment in the Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University from January 2018 to June 2019 were collected. There were 30 liver cancer specimens and paracancer specimens. Real-time PCR was used to detect the expression of CDCA3 in different tissues. CDCA3 interfering RNA sequences and control sequences were transfected into hepatocellular carcinoma cell lines by lip3000 transfection. Cell proliferation was detected by CCK-8 and EdU immunofluorescence staining, and cell cycle was detected by elapse cytology. Results The expression level of CDCA3 in liver cancer tissues was significantly higher than that in paracancer tissues, and the difference was highly statistically significant (P ＜ 0.01). The expression levels of CDCA3 in HepG2, Huh7 and SMMC-7721 cells were significantly higher than those in LO2 cells, with statistically significant differences (P ＜ 0.05 or P ＜ 0.01), while the expression level of CDCA3 in BEL-7402 cells was not statistically significant compared with that in LO2 cells (P ＞ 0.05). The expression of CDCA3 in SMMC-7721 cells down-regulated by SiCDCA3#1 and siCDCA3#2 was statistically significant compared with that in the control group (siNC) (P ＜ 0.05). Therefore, SMMC-7721 cells were selected to complete the follow-up study. After the expression levels of CDCA3 in SMMC-7721 cells were down-regulated by siCDCA3#1 and siCDCA3#2, the number of cell proliferation at 24 h and 48 h was significantly lower than that in the siNC, and the differences were statistically significant (all P ＜ 0.05). And the number of positive cells detected at EdU was significantly lower than that in the siNC. Compared with the siNC, the G1 phase time of SMMC-7721 cell cycle was prolonged after the expression of CDCA3 in SMMC-7721 cell was down-regulated by siCDCA3#2, and the difference was statistically significant (P ＜ 0.05). Conclusion CDCA3 can promote the proliferation of liver cancer cells and is a potential therapeutic target.

Key words： Cell division cycle associated protein 3 Liver cancer Proliferation Cell cycle

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Fang XU Ximing

Cite this article:

LIU Fang XU Ximing. Study on the role of CDCA3 in the proliferation of hepatocellular carcinoma[J]. 中国医药导报, 2020, 17(14): 14-18,30.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I14/14

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[2] Song T. Recent advances in surgical treatment of hepatocellular carcinoma [J]. Drug Discov Ther，2015，9（5）：319-330.
[3] Meng M，Wang H，Zeng X，et al. Stereotactic body radiation therapy：A novel treatment modality for inoperable hepatocellular carcinoma [J]. Drug Discov Ther，2015，9（5）：372-379.
[4] Yang N，Li S，Li G，et al. The role of extracellular vesicles in mediating progression，metastasis and potential treatment of hepatocellular carcinoma[J]. Oncotarget，2017，8（2）：3683-3695.
[5] Zhang MX，Xu XM，Zhang P，et al. Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway [J]. Tumor Biology，2016，37（2）：2023-2035.
[6] Yu TT，Xu XM，Hu Y，et al. Long noncoding RNAs in hepatitis B virus-related hepatocellular carcinoma [J]. World J Gastroenterol，2015，21（23）：7208-7217.
[7] Adams MN，Burgess JT，He Y，et al. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer [J]. J Thorac Oncol. 2017，7（12）： 1071-1084.
[8] Yu J，Hua R，Zhang Y，et al. DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter [J]. J Cell Biochem，2020，121（1）：142-151.
[9] Phan NN，Wang CY，Li KL，et al. Distinct expression of CDCA3，CDCA5，and CDCA8 leads to shorter relapse free survival in breast cancer patient [J]. Oncotarget，2018，9（6）：6977-6992.
[10] Zhang Y，Yin W，Cao W，et al. CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer [J]. Oncol Rep，2019，41（4）：2471-2481.
[11] Li S，Liu X，Liu T，et al. Identification of biomarkers correlated with the TNM staging and overall survival bladder cancer [J]. Front Physiol. 2017，8：947.
[12] Bi L，Zhou B，Li H，et al. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia [J]. BMC Cancer，2018，18（1）：182.
[13] Qian W，Zhang Z，Peng W，et al. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer [J]. Int J Oncol，2018，53（5）：2021-2033.
[14] Matera R，Saif MW. New therapeutic directions for advanced pancreatic cancer： cell cycle inhibitors，stromal modifiers and conjugated therapies [J]. Expert Opin Emerg Drugs，2017，22（3）：223-233.
[15] Itzel T，Scholz P，Maass T，et al. Translating bioinformatics in oncology： guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis [J]. Bioinformatics，2015，31（2）：216-224.
[16] Chen J，Zhu S，Jiang N，et al. HoxB3 promotes prostate cancer cell progression by transactivating CDCA3 [J]. Cancer Lett，2013，330（2）：217-224.
[17] Zhang W，Lu Y，Li X，et al. CDCA3 promotes cell proliferation by activating the NF-κB/cyclin D1 signaling pathway in colorectal cancer [J]. Biochem Biophys Res Commun.，2018，500（2）：196-203.
[18] Hu Q，Fu J，Luo B，et al. OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG，CD9，CCND2 and CDCA3：a bioinformatic analysis combine with RNAi and oligonucleotide microarray [J]. Oncol Rep，2015，33（4）：1965-1975.